Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ACXP 
Acurx Pharmaceuticals LLC (ACXP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/23/2025: ACXP (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $61.7
1 Year Target Price $61.7
| 1 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -36.89% | Avg. Invested days 23 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/23/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 10.35M USD | Price to earnings Ratio - | 1Y Target Price 61.7 |
Price to earnings Ratio - | 1Y Target Price 61.7 | ||
Volume (30-day avg) 3 | Beta -1.29 | 52 Weeks Range 3.80 - 39.20 | Updated Date 10/23/2025 |
52 Weeks Range 3.80 - 39.20 | Updated Date 10/23/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -10.57 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -98.59% | Return on Equity (TTM) -285.94% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1162446 | Price to Sales(TTM) - |
Enterprise Value 1162446 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.54 | Shares Outstanding 1584775 | Shares Floating 1301227 |
Shares Outstanding 1584775 | Shares Floating 1301227 | ||
Percent Insiders 8.12 | Percent Institutions 13.81 |
Upturn AI SWOT
Acurx Pharmaceuticals LLC
Company Overview
History and Background
Acurx Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing new antibiotics for difficult-to-treat infections. Founded in 2017, Acurx is focusing on its lead product candidate, ibezapolstat, for the treatment of Clostridioides difficile infection (CDI).
Core Business Areas
- Antibiotic Development: Focuses on the discovery and development of antibiotics to combat resistant bacteria, particularly Clostridioides difficile (C. diff).
Leadership and Structure
David P. O'Toole is the President and CEO. The company operates with a management team overseeing research and development, clinical trials, and business operations.
Top Products and Market Share
Key Offerings
- Ibezapolstat: An orally administered antibiotic in Phase 3 clinical trials for the treatment of Clostridioides difficile infection (CDI). Competitors include antibiotics such as vancomycin, fidaxomicin, and metronidazole. Market share data is not currently available as the product is not yet approved for commercial sale.
Market Dynamics
Industry Overview
The antibiotic market is driven by the increasing prevalence of antibiotic-resistant bacteria and the need for new treatments for serious infections.
Positioning
Acurx aims to address the unmet medical need in treating CDI with a novel mechanism of action. The company seeks to offer an alternative to existing treatments with potentially improved efficacy and safety profiles.
Total Addressable Market (TAM)
The global Clostridium difficile infection (CDI) treatment market was valued at $1.8 Billion in 2023 and is projected to reach $2.7 billion by 2033. Acurx is positioned to compete for a share of this TAM if ibezapolstat is approved.
Upturn SWOT Analysis
Strengths
- Novel antibiotic candidate with a unique mechanism of action
- Focus on a significant unmet medical need (CDI)
- Experienced management team
Weaknesses
- Reliance on a single product candidate
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on successful clinical trial outcomes and regulatory approval
Opportunities
- Potential to capture a significant share of the CDI treatment market
- Partnerships with larger pharmaceutical companies for commercialization
- Expansion into other antibiotic development programs
Threats
- Competition from existing and emerging CDI treatments
- Regulatory hurdles and potential delays in approval
- Failure to demonstrate efficacy or safety in clinical trials
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- MRK
- SCLX
- PLXD
Competitive Landscape
Acurx faces competition from established pharmaceutical companies with marketed CDI treatments. Its competitive advantage lies in its novel mechanism of action and potential for improved efficacy and safety. The company is in a disadvantage due to its smaller size, lack of market presence, and cash to sustain operation.
Growth Trajectory and Initiatives
Historical Growth: Historical growth can be measured by clinical milestones achieved.
Future Projections: Future growth depends on the success of ibezapolstat in clinical trials and the ability to secure regulatory approval and commercial partnerships.
Recent Initiatives: Advancement of ibezapolstat through Phase 3 clinical trials. Seeking partnerships for commercialization.
Summary
Acurx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing ibezapolstat for CDI. The company is developing a novel antibiotic, but it faces significant risks associated with clinical trials and regulatory approval. Acurx has limited cash and is in a disadvantage position to compete with other companies with existing treatments. However, successful development and commercialization of its drug could create significant value.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC filings
- Company website
- Market research reports
- Analyst reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on your own research and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Acurx Pharmaceuticals LLC
Exchange NASDAQ | Headquaters Staten Island, NY, United States | ||
IPO Launch date 2021-06-25 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://www.acurxpharma.com |
Full time employees 4 | Website https://www.acurxpharma.com | ||
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia; and CCP, multiple product candidates for gram-positive infections. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.